Biotechnology Company Licenses PATH/TOX SYSTEM™

Share Article

Xybion is selected to provide a turnkey solution for the collection, management and reporting of safety assessment data related to human therapeutics research activities.

Xybion Medical Systems Corporation (Xybion), the developer and supplier of PATH/TOX SYSTEM™, a state-of-the-art comprehensive preclinical data management system, announced today that one of the world’s leading international biotechnology companies has selected Xybion to provide a turnkey solution for the collection, management and reporting of safety assessment data related to their human therapeutics research activities being conducted throughout the United States. Respecting our client’s confidentiality requirements, the company’s name is not being disclosed.

“We are delighted that a Fortune 500 company, ranked among the world’s largest pharmaceutical companies, has determined that PATH/TOX SYSTEM is the premier data management solution available today,” said David M. Neglia, President of Xybion. “The award of this highly competitive contract represents a significant achievement and further strengthens Xybion’s position as the leading provider of pre-clinical enterprise solutions."

PATH/TOX SYSTEM is a single solution that addresses all aspects of preclinical data acquisition, management and reporting. It is in use in 9 different countries throughout North America, Europe and Asia. Clients have the flexibility to license those components and options needed to support their study protocols and processes providing a client-centric, custom solution. Xybion’s products and services are industry leaders and are used by the world’s largest and most prestigious, as well as many smaller companies, in the biotechnology, pharmaceutical, chemical and contract research industries to assess compound safety while reducing post-discovery research costs and time to market.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website